Taurolidine

Drug Profile

Taurolidine

Alternative Names: Taurolin

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator Geistlich
  • Class Alkanesulfonic-acids; Antibacterials; Antineoplastics; Thiadiazines
  • Mechanism of Action Lipopolysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Empyema; Peritonitis
  • Phase I/II Periodontitis
  • No development reported Colorectal cancer
  • Discontinued Septic shock

Most Recent Events

  • 31 Jul 2015 No recent reports on development identified - Phase-II for Colorectal cancer in Ireland (IV)
  • 01 Jul 2015 Phase-I/II clinical trials in Periodontitis in USA (IV)
  • 12 Dec 2014 Geistlich plans a phase I/II trial for Periodontitis in USA (NCT02313883)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top